Clinical Trials Browser

Anal Canal Carcinoma × Watchful Waiting × 90 days × Clear all

NCT03233711 2026-03-18

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms